Nuo Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nuo Xu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Chao Leng
Tongji Hospital 9 Hepatic Surgery Center Tongji Medical College Wuhan, China
1 shared publication - Chen Yang
State Key Laboratory of Oncogenes and Related Genes, Department of Liver Surgery & Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine
1 shared publication - Cun Wang
State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute & Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Haigang Geng
Department of Gastrointestinal Cancer Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
1 shared publication - Haiyan Hu
Shanghai Sixth People’s Hospital 4 Department of Oncology Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Hao Feng
Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication
Latest Publications
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF21
Latent Squamous Plasticity Licensed by Chromatin-State Remodeling Dictates Therapeutic Susceptibility in Cholangiocarcinoma
Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (∼1 to 2%), yet its occurrence portends lethal disease progression. In this study, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20% to 30% of patients with iCCA can be classified as STP high and experience ASC-like dismal outcomes. Mechanistically, FOS-like 1 (FOSL1) acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral prostaglandin (PG) E2 accumulation drives neutrophil-mediated FOXP3-negative type I regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immunopermissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235). Significance: Latent squamous plasticity defines a common yet histologically occult high-risk state in iCCA, driven by FOSL1-dependent enhancer reprogramming and coupled to a PGE2-dependent neutrophil–Tr1 immunosuppressive circuit. By integrating STP-based stratification with celecoxib repurposing, this study identifies latent squamous plasticity as a clinically actionable vulnerability to improve iCCA treatment responsiveness.
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF21
Latent Squamous Plasticity Licensed by Chromatin-State Remodeling Dictates Therapeutic Susceptibility in Cholangiocarcinoma
Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (∼1 to 2%), yet its occurrence portends lethal disease progression. In this study, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20% to 30% of patients with iCCA can be classified as STP high and experience ASC-like dismal outcomes. Mechanistically, FOS-like 1 (FOSL1) acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral prostaglandin (PG) E2 accumulation drives neutrophil-mediated FOXP3-negative type I regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immunopermissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235). Significance: Latent squamous plasticity defines a common yet histologically occult high-risk state in iCCA, driven by FOSL1-dependent enhancer reprogramming and coupled to a PGE2-dependent neutrophil–Tr1 immunosuppressive circuit. By integrating STP-based stratification with celecoxib repurposing, this study identifies latent squamous plasticity as a clinically actionable vulnerability to improve iCCA treatment responsiveness.